Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases

Table 1 Demographic details ^a

Group (n)	M/F,n(missing data)	Age at death, yr (mean ± SD)	Sections available,n
Group (n)	M/F,n(missing data)	Age at death, yr (mean ± SD)	Frontal	Temporal	Hippocampal
Controls (32)	14/18	72.0 ± 21.0	19	32	31
AD (46)	23/23	72.0 ± 6.0	46	41	41
MND (25)	20/5	64.3 ± 12.0	17	25	24
FTLD (72)	41/31	65.6 ± 9.1	71	66	60
FTLD-tau (31)	14/14 (3)	67.2 ± 9.6	31	25	25
MAPT (5)	2/3	62.2 ± 5.4	5	4	4
Pick (26)	12/11 (3)	68.3 ± 10.1	26	21	21
FTLD-TDP (41)	26/15	64.7 ± 8.7	40	41	35
Type A (17)	8/9	68.7 ± 4.2	17	17	14
Type B (14)	12/2	58.3 ± 9.0	13	14	12
Type C (10)	6/4	66.5 ± 9.4	10	10	9

^aAD, Alzheimer’s disease; FTLD, Frontotemporal lobar degeneration; FTLD-MAPT, Frontotemporal lobar degeneration with mutations in the microtubule-associated protein tau; MND, Motor neuron disease; FTLD-tau Pick, Frontotemporal lobar degeneration tau with Pick bodies; TDP, Transactive response DNA binding protein 43 proteinopathy (subtypes A, B and C according to Mackenzie et al. [16]).

ISSN: 1758-9193